Tirzepatide (GLP1T)
For Research Use Only
Injectable
A dual GLP-1/GIP receptor agonist peptide investigated in metabolic and endocrine research. Studies compare dual incretin-receptor activation with single-pathway agonists in cell and animal models of insulin signaling and lipid metabolism. Laboratory research areas include: incretin receptor co-activation, metabolic signaling assays, and comparative pharmacology.
Size: 30mg
$350.00
In stockCheckout opens once payment is connected.
Certificates of analysis
No certificate has been published for this product yet.
Research guides
- Tirzepatide as a Dual GIP/GLP-1 Receptor Agonist: What the Published Research ReportsA research-framed overview of published in vitro, animal, and human studies on tirzepatide, a single peptide engineered to engage both the GIP and GLP-1 receptors, covering receptor pharmacology, reported metabolic endpoints in clinical trials, preclinical mechanistic work, and documented tolerability observations.
- Tirzepatide Pharmacokinetics in Animal Models: What the Published Literature ReportsA research-framed summary of published findings on tirzepatide disposition in rats, including a validated LC-MS/MS bioanalytical method, reported terminal half-lives after intravenous and subcutaneous administration, and estimated subcutaneous bioavailability, alongside a scoping review mapping preclinical and clinical evidence for this dual GIP/GLP-1 receptor agonist.
- Tirzepatide: A Research OverviewA research-framed summary of what published reviews, systematic reviews and meta-analyses report about tirzepatide, a dual GIP and GLP-1 receptor agonist, across glycaemic, body-weight, cardiorenal, hepatic and adverse-event endpoints, with each finding labelled by the model in which it was studied.
This product is not for human or animal consumption. Misuse of this product is illegal.